On the stock market since 2019, it operates in the world of health and science. It has 450 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 11% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
The stock trades 58% below its peak. The market has trimmed its expectations for the company.
Sales run at $32.0M a year. A small number, but proof the product has real buyers.
A loss of $193K against $32.0M in annual sales.
The stock sits at $0.27. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, NVLPF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: NVLPF is a high-risk stock — not yet profitable, and its future rides on its product catching on.